trending Market Intelligence /marketintelligence/en/news-insights/trending/7fvkblfcjxzyjagueigt5g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

BioSig Technologies seeks US FDA approval for cardiac recording system

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BioSig Technologies seeks US FDA approval for cardiac recording system

BioSig Technologies Inc. filed a 510(k) application with the U.S. Food and Drug Administration for its PURE EP System.

The Los Angeles-based medical device company is seeking approval for the surface electrocardiogram and intracardiac multichannel recording system, which aims to produce high-fidelity heart recordings during electrophysiology studies and catheter ablation procedures.

Catheter ablation is a procedure to treat atrial fibrillation, the most common form of quivering or irregular heartbeat known as arrhythmia. Atrial fibrillation affects 6.1 million people in the U.S., increasing their risk of stroke by 4 to 5 times.

BioSig Technologies said it has conducted 11 pre-clinical studies and one clinical trial between 2015 and 2018.